Association between pre-pregnancy multimorbidity and adverse maternal outcomes: A systematic review

Hilary K Brown1,2,3, Anthony McKnight2 and Amira Aker1,2

Abstract

Objective: We reviewed the literature on the association between pre-pregnancy multimorbidity (co-occurrence of two or more chronic conditions) and adverse maternal outcomes in pregnancy and postpartum.

Data sources: Medline, EMBASE, and CINAHL were searched from inception to September, 2021.

Study selection: Observational studies were eligible if they reported on the association between ≥ 2 co-occurring chronic conditions diagnosed before conception and any adverse maternal outcome in pregnancy or within 365 days of childbirth, had a comparison group, were peer-reviewed, and were written in English.

Data extraction and synthesis: Two reviewers used standardized instruments to extract data and rate study quality and the certainty of evidence. A narrative synthesis was performed.

Results: Of 6,381 studies retrieved, seven met our criteria. There were two prospective cohort studies, two retrospective cohort studies, and 3 cross-sectional studies, conducted in the United States (n=6) and Canada (n=1), and ranging in size from n=3,110 to n=57,326,681. Studies showed a dose-response relation between the number of co-occurring chronic conditions and risk of adverse maternal outcomes, including severe maternal morbidity or mortality, hypertensive disorders of pregnancy, and acute health care use in the perinatal period. Study quality was rated as strong (n=1), moderate (n=4), or weak (n=2), and the certainty of evidence was very low to moderate.

Conclusion: Given the increasing prevalence of chronic disease risk factors such as advanced maternal age and obesity, more research is needed to understand the impact of pre-pregnancy multimorbidity on maternal health so that appropriate preconception and perinatal supports can be developed.

Keywords
Comorbidity, multimorbidity, pregnancy, severe maternal morbidity, maternal mortality, systematic review

Introduction

The prevalence of chronic conditions such as diabetes mellitus, cardiovascular disease, asthma, and mental illness is steadily increasing worldwide, now accounting for 50% of the global disease burden.1 In industrialized countries, half of adults over 20 years have at least one chronic condition.2 The co-occurrence of two or more chronic conditions, i.e., multimorbidity, is a growing public health concern, with the prevalence increasing from 25% in 2003 to 32% in 2016.3 Multimorbidity was...
Initially considered to be a phenomenon of aging,4 yet, studies have shown that while multimorbidity risk increases with age, individuals are affected across the life course, with as many as 18% of 18 to 49-year-olds having multimorbidity.3 Growing evidence suggests individuals with multimorbidity account for a disproportionate amount of health care use and cost. In the general population, there is a dose-response relation between the number of chronic conditions and rates of hospitalization, risk of death, and magnitude of attributable health care costs.5-7 These patterns reveal gaps in primary care of persons with multimorbidity.

The impact of multimorbidity on maternal outcomes in pregnancy and postpartum is less understood. Increasing rates of maternal mortality,8 severe maternal morbidity,8 and acute perinatal health care use9 have prompted investigations into the role of chronic disease in explaining these outcomes. Studies from Canada,10 the United Kingdom,11 and the United States12 have consistently shown that chronic diseases, and in particular cardiovascular disease, chronic hypertension, and diabetes mellitus, are top contributors. Yet, while chronic conditions are prevalent and are known to co-occur, obstetric research and practice remain focused on the impact of single chronic conditions rather than on their combined impacts.13 Emerging evidence suggests this is an important oversight, with a number of studies from the United States, the United Kingdom, and Germany confirming that as many as one in five women enter pregnancy with two or more chronic conditions.14-16 High rates of adverse maternal outcomes among women with multimorbidity would indicate the need for better preventive efforts to address modifiable risk factors in the preconception period and patient-centered supports perinatally.

We performed a systematic review of the literature on the association between pre-pregnancy multimorbidity and adverse maternal outcomes in pregnancy and postpartum.

Methods and materials

Information sources and search strategy

This systematic review was prospectively registered in the PROSPERO database (ID: CRD42019137416). We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)17 guidelines to inform our review. In consultation with a librarian, controlled vocabulary and plain language keywords were developed for the concepts of multimorbidity (e.g., multimorbidity, multiple chronic conditions)18 and adverse maternal outcomes (e.g., maternal mortality, severe maternal morbidity, perinatal hospital use) (Table 1). We searched Medline, EMBASE, and CINAHL from inception to September 14, 2021. One author performed the initial database search. Two authors independently reviewed the results and searched the bibliographies of selected studies to identify additional studies missed in the database search.

Eligibility criteria and study selection

Two authors independently reviewed titles and abstracts. To be included, studies were required to (1) examine, as an exposure, multimorbidity diagnosed before conception; (2) examine, as an outcome, any maternal medical complication, acute health care use, or death between conception and 365 days postpartum; (3) have a comparison group of women with no chronic conditions; (4) be peer-reviewed; and (5) be written in English. To be consistent with established multimorbidity frameworks, which define multimorbidity as the presence of ≥2 chronic conditions from among a list of several conditions,16 we excluded studies only examining “one or more” chronic conditions (i.e., not allowing differentiation of one vs. multiple conditions) and those in which the conditions examined were not chronic (e.g., those that included gestational diabetes or gestational hypertension). While we initially planned to exclude studies that examined a specific comorbidity (e.g., diabetes and depression) without further evaluation of other conditions, a preliminary review of our search results revealed very few studies examining multimorbidity from among a long list of possible chronic conditions; therefore, within the scope of the search strategy, where specific combinations of morbidities were identified, the outcomes for these studies were also reported. Last, we excluded studies that examined offspring outcomes only, since our focus was on maternal health.

Data extraction

After establishing consensus on the list of eligible studies via full text review, two authors independently extracted available study data using a standardized form, created a priori to reflect the elements of the Strengthening the Reporting of Observational Studies in Epidemiology statement.19 The form included: study location, study period, study design, data sources, sample size, response rates, follow-up rates, missing data rates, inclusion criteria, multimorbidity definition, outcome definition(s), and confounders controlled for. We also extracted outcome event rates and measures of effect, where available. Where information was unclear or missing, we contacted study authors by email for clarification. Discrepancies in data extraction were discussed by the authors until consensus was reached.

Quality assessment

Two authors independently conducted a quality assessment of each article using the Effective Public Health Practice Project Quality Assessment Tool.20 Study quality was rated based on study design, risk of selection bias (representativeness of the cohort, response rate), control for confounding, risk of detection bias (assessment of the outcome), and risk of attrition bias (loss to follow-up). For control for confounding, we identified variables a priori that are associated with chronic disease risk and with adverse
maternal outcomes: maternal age, socioeconomic status, race/ethnicity, and health behaviours (e.g., smoking, BMI). As in previous research, we rated studies overall as being weak (≥ 2 individual categories rated as weak), moderate (1 category rated as weak), or strong in quality (0 categories rated as weak).

**Data synthesis**

We planned to use random effects models to calculate pooled unadjusted and adjusted odds ratios for the association between multimorbidity and adverse maternal outcomes. However, exposure and outcome definitions were not homogeneous for a sufficient number of studies to conduct a meta-analysis. We therefore described the study results using a narrative synthesis following Synthesis Without Meta-analysis (SWiM) guidelines.

**Grading of the evidence**

We used the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach, modified for narrative syntheses, to ascertain the certainty of evidence. By default, studies started at low-certainty evidence and were then downgraded or upgraded based on a priori criteria. Criteria for downgrading evidence were methodological limitations as identified by the Effective Public Health Practice Project Quality Assessment Tool, indirectness (i.e., dissimilarity of research evidence from clinical practice in terms of population, exposure, or outcomes), imprecision (i.e., 95% confidence intervals including the null value, or a small number of events of < 400), inconsistency (i.e., differences in the magnitude of effects across studies), and likelihood of publication bias (i.e., the presence of only small positive studies). Criteria for upgrading were a large effect size (i.e., OR or RR > 2.0), a dose-response relationship between exposure and outcome, and attenuation by plausible confounders.

**Results**

**Study selection**

Figure 1 shows the study selection process. Our database search revealed 6,381 unique studies, of which 6,298 were excluded due to lack of relevance. Eighty-three full-text articles were reviewed. Of these, we excluded studies that examined: (1) “one or more” chronic conditions (n=25), (2) conditions that were not clearly chronic (n=37), and (3) offspring outcomes only (n=3). We also excluded...
Study characteristics

Study characteristics are described in Table 2. Six studies were conducted in the United States27-32 and one in Canada.33 There were two prospective cohort studies,29,31 two retrospective cohort studies,32,33 and three cross-sectional studies.27,28,30 Sample sizes ranged from 3,11029 to 57,326,681 women.32 Two studies defined multimorbidity as ≥ 2 chronic conditions from among a list of 8 to 16 eligible conditions;27,28 two studies used comorbidity indices applied to pre-pregnancy diagnoses (i.e., the Elixhauser Comorbidity Index and the Johns Hopkins Adjusted Clinical Group System Aggregated Diagnosis Groups [ADGs]),30,33 and three studies measured combinations of specific co-occurring conditions,29,31,32 better described as comorbidity (i.e., asthma and migraine; autoimmune disease and depression; sickle cell disease and HIV). Outcomes were severe maternal morbidity or maternal mortality (n=3);27,28,30 other composite measures of pregnancy complications (n=1);32 hypertensive disorders of pregnancy (n=2);29,31,32 and health services indicators of complications (n=2; i.e., perinatal emergency department visits, delivery hospitalization length of stay, and hospital transfer).27,29 All studies controlled for confounding to some extent.

Quality of included studies

Study quality is described in Table 1. Studies were rated overall as strong (n=1),32 moderate (n=4),28,30,31,33 or weak (n=2)27,29 on the basis of study design, selection bias, confounding, detection bias, and attrition bias. Three of the studies were cross-sectional, leading to weak study design ratings.27,28,30 In terms of selection bias, one of the prospective cohort studies did not report response rate and was rated as weak;29 the other had a response rate of 79% and was rated as moderate.31 The remaining studies were population-based. Two studies only controlled for 50% of the confounder categories identified a priori as being important and were rated as weak.27,33 The remainder controlled for most (n=4)28,30,31,32 or all (n=1)29 of the confounder categories. Regarding detection bias, all of the studies used established health administrative datasets and/or clinical data and were rated as moderate (n=5),27,28,30,32 or strong (n=2).29,31 Finally, neither of the prospective cohort studies reported follow-up rates,29,31 resulting in weak ratings for attrition bias for these studies.

Synthesis of results

Studies generally found increasing risk of adverse maternal outcomes with an increasing number of chronic conditions. This was most clearly seen for severe maternal morbidity and mortality.27,28,30 Hospital transfer,27 and emergency department visits33 (Table 2). Admon et al.27 reported that rates of severe maternal morbidity and mortality were significantly higher in women with multimorbidity than those with one chronic condition or none, even after adjustment. The same associations were seen in a second study by Admon et al.,28 wherein results were stratified by race/ethnicity. In this study, the authors found the dose-response relation between the number of chronic conditions and risk of severe maternal morbidity was strongest among non-Hispanic Black women, followed by Hispanic, American Indian/Alaska Native, Asian/Pacific Islander, and White populations. Likewise, Brown et al.30 demonstrated a clear dose-response relation after adjustment between the number of chronic conditions (from 0 to ≥ 3 on the Elixhauser Comorbidity Index) and rates of severe maternal

Table 1. Study quality.

| Study            | Study design | Selection bias | Confounding | Detection bias | Attrition bias | Overall rating |
|------------------|--------------|----------------|-------------|----------------|----------------|----------------|
| Admon 2018 a27   | Weak         | Strong         | Weak        | Moderate       | Strong         | Weak           |
| Admon 2018 b28   | Weak         | Strong         | Moderate    | Moderate       | Strong         | Moderate       |
| Bandoli 201729   | Moderate     | Weak           | Strong      | Strong         | Weak           | Weak           |
| Brown 202030     | Weak         | Moderate       | Moderate    | Strong         | Strong         | Moderate       |
| Czerwinski 201231| Moderate     | Moderate       | Moderate    | Strong         | Weak           | Moderate       |
| Prophet 201832   | Moderate     | Strong         | Moderate    | Strong         | Strong         | Strong         |
| Varner 202033    | Moderate     | Strong         | Weak        | Moderate       | Moderate       | Moderate       |

Notes: Quality related to study design is rated as moderate for cohort and case-control studies and weak for cross-sectional studies; Quality related to selection bias is rated as strong if the study sample is likely representative and the response rate is ≥ 80%, moderate if study sample is somewhat representative or response rate is 60-79%, and weak if the study sample is self-referred or volunteers or the response rate is < 60% or not reported; Quality related to control for confounding is rated as strong if ≥ 80% of confounders are controlled for, and weak if < 60% of confounders are controlled for; Quality related to detection bias is rated as strong if clinical diagnoses are used, moderate if population-based data are used, and weak if self-reported data are used; Quality related to attrition bias is rated as strong if follow-up is ≥ 80% or the study is a retrospective cohort study or cross-sectional study, moderate if follow-up is 60-79%, and weak if follow-up is < 60% or not reported. Overall rating is weak if ≥ 2 components are rated as weak, moderate if 1 component is rated as weak, and high if 0 components are rated as weak.
morbidity overall and without blood transfusion. Admon et al.\textsuperscript{27} also found a dose-response relation between the number of chronic conditions and rates of hospital transfer. Finally, Varner et al.\textsuperscript{33} showed a similar pattern for Johns Hopkins Adjusted Clinical Group System ADGs and risk of one, two, and three perinatal emergency department visits, after adjustment.

Findings were mostly similar for “any” pregnancy complication, and various definitions of preeclampsia. These latter outcomes were examined by studies of specific combinations of chronic conditions (Table 2). Prophet et al.\textsuperscript{32} found the odds of any pregnancy complication, preeclampsia, and severe preeclampsia were higher in women with sickle cell disease and HIV, compared to those with either or neither condition, after adjustment. Likewise, Czerwinski et al.\textsuperscript{31} showed individuals with migraine and asthma had the highest elevated odds of preeclampsia and pregnancy-induced hypertension, compared to individuals with either or neither condition, after adjustment. Only Bandoli et al.’s results did not support this sort of dose-response relationship, reporting that the risk of preeclampsia did not appear to be meaningfully greater in women with

### Table 2. Study Findings.

| Outcome                        | Study (details)                      | Exposure groups                  | % with outcome | OR or RR (95% CI) | aOR or aRR (95% CI) |
|-------------------------------|--------------------------------------|----------------------------------|----------------|-------------------|---------------------|
| **Any pregnancy complication** | Prophet 2018\textsuperscript{27}     | HIV + sickle cell disease        | 15.2           | NR                | 1.89 (0.82-4.33)    |
|                               |                                      | HIV only                         | 8.4            | NR                | 0.95 (0.89-1.01)    |
|                               |                                      | Sickle cell disease only         | 9.8            | NR                | 1.11 (1.03-1.18)    |
|                               |                                      | Neither condition                | 8.1            | [Referent]        | [Referent]          |
| **Severe maternal morbidity or mortality** | Admon 2018 a\textsuperscript{22}       | \(\geq 2\) chronic conditions   | 6.4            | NR                | NR                  |
|                               |                                      | 1 chronic condition              | 3.0            | NR                | NR                  |
|                               |                                      | No chronic conditions            | 1.7            | [Referent]        | [Referent]          |
|                               | Admon 2018 b\textsuperscript{13} (non-Hispanic White) | \(\geq 2\) chronic conditions   | 2.9            | NR                | NR                  |
|                               |                                      | 1 physical condition             | 1.8            | NR                | NR                  |
|                               |                                      | 1 behavioural condition          | 2.4            | NR                | NR                  |
|                               |                                      | No chronic conditions            | 1.3            | [Referent]        | [Referent]          |
|                               | Admon 2018 b\textsuperscript{13} (non-Hispanic Black) | \(\geq 2\) chronic conditions   | 5.5            | NR                | NR                  |
|                               |                                      | 1 physical condition             | 3.2            | NR                | NR                  |
|                               |                                      | 1 behavioural condition          | 4.0            | NR                | NR                  |
|                               |                                      | No chronic conditions            | 2.2            | [Referent]        | [Referent]          |
|                               | Admon 2018 b\textsuperscript{23} (Hispanic) | \(\geq 2\) chronic conditions   | 4.7            | NR                | NR                  |
|                               |                                      | 1 physical condition             | 2.9            | NR                | NR                  |
|                               |                                      | 1 behavioural condition          | 3.1            | NR                | NR                  |
|                               |                                      | No chronic conditions            | 1.6            | [Referent]        | [Referent]          |
|                               | Admon 2018 b\textsuperscript{23} (Asian / Pacific Islander) | \(\geq 2\) chronic conditions   | 5.4            | NR                | NR                  |
|                               |                                      | 1 physical condition             | 2.8            | NR                | NR                  |
|                               |                                      | 1 behavioural condition          | 3.6            | NR                | NR                  |
|                               |                                      | No chronic conditions            | 1.5            | [Referent]        | [Referent]          |
|                               | Admon 2018 b\textsuperscript{23} (Al/AAN) | \(\geq 2\) chronic conditions   | 4.1            | NR                | NR                  |
|                               |                                      | 1 physical condition             | 2.2            | NR                | NR                  |
|                               |                                      | 1 behavioural condition          | 3.3            | NR                | NR                  |
|                               |                                      | No chronic conditions            | 2.0            | [Referent]        | [Referent]          |
|                               | Brown 2020\textsuperscript{25}       | \(\geq 3\) comorbidities        | 5.6            | 12.1 (11.5-12.7)  | 9.1 (8.7-9.6)       |
|                               |                                      | 2 comorbidities                 | 3.8            | 8.1 (7.8-8.5)     | 6.6 (6.3-6.9)       |
|                               |                                      | 1 comorbidity                   | 2.4            | 5.0 (4.8-5.2)     | 4.4 (4.2-4.6)       |
|                               |                                      | 0 comorbidities                 | 0.5            | [Referent]        | [Referent]          |
|                               | Brown 2020\textsuperscript{25} (no blood transfusion) | \(\geq 3\) comorbidities        | 2.4            | 15.1 (14.0-16.3)  | 9.7 (8.9-10.5)      |
|                               |                                      | 2 comorbidities                 | 1.1            | 6.6 (6.1-7.1)     | 4.8 (4.3-5.2)       |
|                               |                                      | 1 comorbidity                   | 0.6            | 3.8 (3.6-4.1)     | 3.1 (2.9-3.3)       |
|                               |                                      | 0 comorbidities                 | 0.2            | [Referent]        | [Referent]          |
| Outcome Study (details) | Exposure groups | % with outcome | OR or RR (95% CI) | aOR or aRR (95% CI) |
|-------------------------|-----------------|----------------|-------------------|--------------------|
| **Preeclampsia and related conditions** | | | | |
| Bandoli 201724 (any preeclampsia) | Crohn’s disease + depression | NR | NR | NR |
| | Crohn’s disease | NR | NR | 1.82 (1.01-3.30) |
| | Neither condition | NR | [Referent] | [Referent] |
| | Psoriasis + depression | NR | NR | 1.39 (0.25-7.62) |
| | Psoriasis only | NR | NR | 1.58 (0.86-2.89) |
| | Neither condition | NR | [Referent] | [Referent] |
| | Rheumatoid arthritis + depression | NR | NR | 1.08 (0.21-5.55) |
| | Rheumatoid arthritis only | NR | NR | 1.65 (1.04-2.63) |
| | Neither condition | NR | [Referent] | [Referent] |
| Czerwinski 201226 (any preeclampsia) | Migraine + asthma | 8.9 | 3.26 (1.52-6.99) | 3.77 (1.61-8.82) |
| | Migraine only | 3.8 | 1.32 (0.79-2.22) | 0.89 (0.49-1.63) |
| | Asthma only | 5.8 | 2.05 (1.23-3.41) | 2.00 (1.14-3.49) |
| | Neither condition | 2.9 | [Referent] | [Referent] |
| Czerwinski 201226 (PIH) | Migraine + asthma | 17.2 | 2.98 (1.73-5.15) | 2.55 (1.40-4.63) |
| | Migraine only | 10.5 | 1.68 (1.22-2.31) | 1.21 (0.85-1.74) |
| | Asthma only | 7.6 | 1.19 (0.78-1.82) | 1.03 (0.66-1.62) |
| | Neither condition | 6.5 | [Referent] | [Referent] |
| Prophet 201827 (any preeclampsia) | HIV + sickle cell disease | 12.9 | | 3.62 (1.51-8.69) |
| | HIV only | 3.5 | NR | 0.86 (0.78-0.96) |
| | Sickle cell disease only | 5.3 | NR | 1.20 (1.10-1.30) |
| | Neither condition | 3.5 | [Referent] | [Referent] |
| Prophet 201827 (mild preeclampsia) | HIV + sickle cell disease | 6.3 | NR | 2.73 (0.97-7.66) |
| | HIV only | 1.9 | NR | 0.76 (0.67-0.86) |
| | Sickle cell disease only | 2.4 | NR | 0.93 (0.81-1.05) |
| | Neither condition | 2.3 | [Referent] | [Referent] |
| Prophet 201827 (severe preeclampsia) | HIV + sickle cell disease | 6.6 | NR | 4.28 (1.35-13.62) |
| | HIV only | 1.7 | NR | 1.02 (0.90-1.16) |
| | Sickle cell disease only | 2.7 | NR | 1.61 (1.44-1.79) |
| | Neither condition | 1.2 | [Referent] | [Referent] |
| **Hospital transfer** | | | | |
| Admon 2018 a22 | ≥ 2 chronic conditions | 3.5 | NR | NR |
| | 1 chronic condition | 2.0 | NR | NR |
| | No chronic conditions | 1.1 | [Referent] | [Referent] |
| **Perinatal emergency department visit** | | | | |
| Varner 2020a38 (1 visit) | 7-32 ADGs | 21.3 | NR | 1.97 (1.92-2.03) |
| | 5-6 ADGs | 22.8 | NR | 1.61 (1.59-1.64) |
| | 3-4 ADGs | 22.2 | NR | 1.33 (1.32-1.34) |
| | ≤ 2 ADGs | 19.7 | [Referent] | [Referent] |
| Varner 2020a38 (2 visits) | 7-32 ADGs | 14.5 | NR | 2.78 (2.70-2.87) |
| | 5-6 ADGs | 13.7 | NR | 2.01 (1.98-2.04) |
| | 3-4 ADGs | 12.0 | NR | 1.49 (1.47-1.50) |
| | ≤ 2 ADGs | 9.5 | [Referent] | [Referent] |
| Varner 2020a38 (3 visits) | 7-32 ADGs | 29.4 | NR | 7.59 (7.39-7.78) |
| | 5-6 ADGs | 18.0 | NR | 3.55 (3.49-3.61) |
| | 3-4 ADGs | 11.9 | NR | 1.99 (1.97-2.01) |
| | ≤ 2 ADGs | 7.1 | [Referent] | [Referent] |

Abbreviations: ADG = aggregated diagnosis group; CI = confidence interval; OR = odds ratio; NR = not reported; PIH = pregnancy-induced hypertension; RR = risk ratio.
both autoimmune disease and depression, compared to those with autoimmune disease only or neither autoimmune disease nor depression.29

Summary of evidence

The GRADE summary of evidence is shown in Table 3. The evidence for severe maternal morbidity and mortality was rated as having moderate certainty. While the evidence was downgraded due to methodological limitations, upgrades were also awarded because of large effects and the clear dose-response relationship between the number of chronic conditions and risks of the outcome. The evidence for perinatal emergency department visits was also upgraded to moderate certainty due to large effects and clear dose-response pattern. The remaining outcomes were rated as having low or very low certainty due to downgrades resulting from methodological limitations and inconsistency.

Discussion

Main findings

In this systematic review, we identified seven studies examining the association between pre-pregnancy multimorbidity and adverse maternal outcomes in pregnancy and the postpartum period. Findings suggested that women with multimorbidity are at increased risk, compared to those with one or no chronic conditions, for severe maternal morbidity or mortality and emergency department visits in the perinatal period, with less certainty for other outcomes. Notably, only four of our studies defined multimorbidity using an adequate list of potential conditions; three studies examined specific comorbidities without consideration of other conditions. Several studies were excluded from our review because they examined one or more chronic conditions, or they included conditions that were not chronic (e.g., gestational diabetes). Given the high prevalence of multimorbidity in obstetric populations14-16 as well as the preliminary findings of the studies included in this review, there is a need for more research examining the risks of adverse maternal outcomes in women with two or more conditions that pre-date the pregnancy, from among a comprehensive list of conditions.

Comparison with existing literature

Our findings build on a growing body of literature in the general population showing that multimorbidity is associated with excess morbidity and mortality risk. Studies have shown that, across age groups, as the number of chronic conditions increases, the rate of acute health care use, length of hospital stay, and risk of mortality increases, and quality of life decreases.5-7 Outside of pregnancy, multimorbidity is also associated with high health care costs. One population-based study in Ontario, Canada, for example, found that multimorbidity accounts for 68% of overall health care costs.7 In individuals less than 65 years of age, having a
second chronic condition (vs. 1) adds an extra $377 CAD in health care costs, and having a fifth (vs. 4) adds $2,073 CAD annually.7 A handful of studies have confirmed the rising prevalence of multimorbidity in obstetric populations. Using the National Inpatient Sample, Admon et al.14 found the prevalence of multimorbidity increased from 4.7 to 8.1 per 1,000 deliveries between 2005 and 2014. In a German study, Kersten et al.15 used self-reported and chart data on all chronic conditions from respondents to the cross-sectional Survey of Neonates in Pomerania to show that 5.3% of pregnant women had 2 chronic conditions, and 2.2% had 3 or more. Finally, in a study from the United Kingdom using three population-based primary care data-sets, the prevalence of multimorbidity in the year before pregnancy ranged from 17.0% to 24.2%.16 However, despite clear importance in terms of frequency, the impact of multimorbidity on maternal outcomes has received minimal research attention.

Reasons for findings

There are several mechanisms by which multimorbidity may increase the risk of adverse maternal outcomes relative to women with one or no chronic conditions. Potential biological mechanisms relate to the substantial physiological changes that accompany pregnancy, including cardiovascular, respiratory, and endocrine changes.34 Such changes have been shown to complicate the perinatal health of women with preexisting conditions,35 and may lead to even greater risk of complications in women with chronic conditions affecting more than one body system, particularly those with other risk factors, such as obesity, that may be more common in women with multiple chronic conditions. Further, women with multimorbidity may require multi-drug regimens that may interact in ways that are not well-understood in pregnant populations and could increase the risk of adverse side effects causing pregnancy complications.36 Finally, from a health systems perspective, models of health care delivery are typically oriented toward single, disease-specific processes and may be ill-equipped to address the complex interaction of multiple chronic conditions in pregnancy.37 In the perinatal period, this may lead to complications because of poor disease management. Further research is needed to explore these mechanisms in obstetric populations.

Research implications

Our findings have implications for measurement of multimorbidity in obstetric research. While we identified several studies that examined the impact of co-occurring conditions on pregnancy outcomes, most failed to follow established definitions of multimorbidity.16 Thirty-seven studies used obstetric comorbidity indices38 that included both chronic conditions and conditions arising in pregnancy, such as gestational diabetes. While such studies provide data broadly relevant to the clinical care of women with complex pregnancies, they have limited utility for understanding how the growing burden of chronic disease impacts maternal health, which has implications for preconception counseling and disease management. Likewise, 25 studies were excluded because they examined “one or more” chronic conditions, making it impossible to discern the impact of multiple chronic conditions, whose combined effects could be very different than that of a single chronic condition. Because of the small number of studies using a strict definition of multimorbidity,18 we decided to also include studies examining specific comorbidities (e.g., asthma and migraine). While such studies are relevant to understanding specific co-occurring conditions and their clinical considerations (e.g., drug-drug interactions), they only hint at the issue of the dose-response relationship between the number of chronic conditions and risk of adverse maternal outcomes that is seen using comprehensive definitions of multimorbidity. In a systematic review of multimorbidity studies in the general population, Fortin et al.18 showed that use of different definitions of multimorbidity resulted in considerable heterogeneity in the reported prevalence of multimorbidity. They recommended the inclusion of at least 12 chronic conditions in definitions of multimorbidity, and the use of both “2 or more” and “3 or more” chronic conditions as the cut-off to identify the presence of multimorbidity. Such definitions could be applied in obstetric settings.

Clinical implications

Internationally, preconception care guidelines emphasize the need to manage chronic conditions before pregnancy, with coordinated care across the perinatal period to avoid adverse outcomes.39,40 However, as is the case in the broader health care system,41,42 preconception and perinatal care are typically organized around the management of single chronic conditions.41 The increasing prevalence of risk factors for multimorbidity, including advanced maternal age and obesity,44,45 suggests that health care strategies to address the needs of women with multimorbidity will become increasingly important. Outside of pregnancy, collaborative, multidisciplinary approaches have been shown to be effective in the management of multimorbidity.41 These approaches include clinical guidelines and health care strategies developed to manage commonly co-occurring clusters of conditions, with particular attention to the biological mechanisms underlying the co-occurrence of these conditions as well as common issues such as drug-drug interactions.42,43 If more high-quality research confirms the findings of the current systematic review, these data would demonstrate the need for such care strategies for
the management of multimorbidity in pregnancy and the postpartum period.

Strengths and limitations

Strengths of our study include the comprehensive literature search using a validated search strategy for multimorbidity. However, we could have missed studies examining multiple chronic conditions if they did not use the terms included in our list of plain language keywords and controlled vocabulary. We initially planned to exclude studies that examined a specific comorbidity (e.g., asthma and migraine) without further evaluation of other conditions; however, an initial review of our search results showed few studies examining multimorbidity from among a long list of possible conditions. Within the scope of the search strategy, where specific combinations of comorbidities were identified, we thus also reported the outcomes for these studies. However, the search itself was not designed for examination of specific combinations of comorbidities. Our search was also restricted to papers written in English, which could have resulted in the exclusion of papers from developing countries where patterns and impacts of pre-pregnancy multimorbidity may differ. Given the heterogeneity in the studies identified, we were unable to conduct a meta-analysis, nor could we formally assess the risk of publication bias using a funnel plot. The studies included in our review were also limited by confounding and possible selection or attrition bias. Certainty of evidence was evaluated using the GRADE approach modified for narrative syntheses. However, given the small number of studies available for any given outcome, no specific recommendations can be drawn.

Conclusion

Our systematic review of seven studies suggests a dose-response relationship between the number of pre-pregnancy chronic conditions and risks of adverse maternal outcomes in pregnancy and postpartum. Given the increasing prevalence of chronic disease risk factors such as advanced maternal age and obesity, more research is urgently needed to understand the impact of multimorbidity on maternal health so that appropriate supports can be developed.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was undertaken, in part, thanks to funding from the Canada Research Chairs Program to Dr. Hilary K. Brown.

ORCID iD

Hilary K Brown https://orcid.org/0000-0002-8690-5841

Supplemental Material

Supplemental material for this article is available online.

References

1. Benziger CP, Roth GA and Moran AE. The global burden of disease study and the preventable burden of NCD. Global Heart 2016; 11(4): 393–397.
2. Health Canada. Prevalence of chronic diseases among Canadian adults. Ottawa, ON; Health Canada; 2019.
3. Pefoyo Kone A, Mondor L, Maxwell C, et al. Rising burden of multimorbidity and related sociodemographic factors: A repeated cross-sectional study of Ontarians. Can J Public Health 2021; 112: 737–747.
4. Wolff JL, Starfield B and Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Int Med 2002; 162(20): 2269–2276.
5. Agborsangaya CB, Lau D, Lahtinen M, et al. Health-related quality of life and healthcare utilization in multimorbidity: results of a cross-sectional survey. Qual Life Res 2013; 22(4): 791–799.
6. Gruneir A, Bronskill SE, Maxwell CJ, et al. The association between multimorbidity and hospitalization is modified by individual demographics and physician continuity of care: a retrospective cohort study. BMC Health Serv Res 2016; 16(1): 154.
7. Thavorn K, Maxwell CJ, Gruneir A, et al. Effect of sociodemographic factors on the association between multimorbidity and healthcare costs: a population-based, retrospective cohort study. BMJ Open 2017; 7(10): e017264.
8. Aoyama K, Ray JG, Pinto R, et al. Temporal variations in incidence and outcomes of critical illness among pregnant and postpartum women in Canada: a population-based observational study. J Obstet Gynecol Can 2019; 41(5): 631–640.
9. Brousseau EC, Danilack V, Cai F and Matteson KA. Emergency department visits for postpartum complications. J Women’s Health 2018; 27(3): 253–257.
10. Wen SW, Huang L, Liston R, et al. Severe maternal morbidity in Canada, 1991–2001. CMAJ 2005; 173(7): 759–764.
11. McClure J, Cooper G, Clutton-Brock T, et al. Saving mothers’ lives: reviewing maternal deaths to make motherhood safer: 2000–8: a review. Br J Anesth 2011; 107(2): 127–132.
12. Creanga AA, Berg CJ, Ko JY, et al. Maternal mortality and morbidity in the United States: where are we now? J Women’s Health 2014; 23(1): 3–9.
13. Beeson JG, Homer CSE, Morgan C, et al. Multiple morbidities in pregnancy: Time for research, innovation, and action. PLoS Med 2018; 15(9): e1002665.
14. Admon LK, Winkelman TN, Moniz MH, et al. Disparities in chronic conditions among women hospitalized for delivery in the United States, 2005-2014. Obstet Gynecol 2017; 130(6): 1319–1326.

15. Kersten I, Lange AE, Haas JP, et al. Chronic diseases in pregnant women: prevalence and birth outcomes based on the SNPstudy. BMC Pregnancy Childbirth 2014; 14(1): 75.

16. Lee SI, Azcoaga-Lorenzo A, Agrawal U, et al. on behalf of the MuM-PreDiCT Group. Epidemiology of pre-existing multimorbidity in pregnant women in the UK in 2018: A population-based cross-sectional study. BMC Pregnancy Childbirth 2022; 22: 120.

17. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6(7): e1000097.

18. Fortin M, Stewart M, Poitras M-E, et al. A systematic review of prevalence studies on multimorbidity: toward a more uniform methodology. Ann Fam Med 2012; 10(2): 142–151.

19. Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Int Med 2007; 147(8): 573–577.

20. Armijo-Olivo S, Stiles CR, Hagen NA, et al. Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool. J Eval Clin Pract 2012; 18(1): 12–18.

21. Brown HK, Qazilbash A, Rahim N, et al. Chronic medical conditions and peripartum mental illness: A systematic review and meta-analysis. Am J Epidemiol 2018; 187(9): 2060–2068.

22. Falah-Hassani K, Shiri R, Vigod S, et al. Prevalence of postpartum depression among immigrant women: a systematic review and meta-analysis. J Psychiatr Res 2015; 70: 67–82.

23. Campbell M, McKenzie JE, Snowden A, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: Reporting guideline. BMJ 2020; 368: 16890.

24. GRADE Working Group. Grading quality of evidence and strength of recommendations. Br Med J 2004; 328: 1490–1494.

25. Murad MH, Mustafa RA, Schunemann H, et al. Rating the certainty of evidence in the absence of a single estimate of effect. Evidence Based Med 2017; 22(3): 85–87.

26. Schunemann H, Brozek J, Guyatt G, et al. GRADE handbook. Accessed 15 March 2022  https://gdtGRADEpro.org/app/handbook/handbook.html.

27. Admon LK, Winkelman TN, Heisler M, et al. Obstetric outcomes and delivery-related health care utilization and costs among pregnant women with multiple chronic conditions. Prev Chronic Dis 2018; 15: E21.

28. Admon LK, Winkelman TNA, Zivin K, et al. Racial and ethnic disparities in the incidence of severe maternal morbidity in the United States, 2012-2015. Obstet Gynecol 2018; 132(5): 1158-1166.

29. Bandoli G and Chambers CD. Autoimmune conditions and comorbid depression in pregnancy: examining the risk of preterm birth and preeclampsia. J Perinatol 2017; 37(10): 1082-1087.

30. Brown CC, Adams CE, George KE, et al. Associations between comorbidities and severe maternal morbidity. Obstet Gynecol 2020; 136: 892–901.

31. Czerwinski S, Gollero J, Qui C, et al. Migraine-asthma comorbidity and risk of hypertensive disorders of pregnancy. J Pregnancy 2012; 2012: 858097.

32. Prophet J, Kelly K, Domingo J, et al. Severe pre-eclampsia among pregnant women with sickle cell disease and HIV. Preg Hypertension 2018; 11: 87–91.

33. Vaner CE, Park AL, Little D, et al. Emergency department use by pregnant women in Ontario: A retrospective population-based cohort study. CMAJ Open 2020; 8(2): e304-e312.

34. Soma-Pillay P, Catherine N-P, Tolppanen H, et al. Physiological changes in pregnancy. Cardiovase J Afr 2016; 27(2): 89.

35. Karanmermer Y and Roos-Hesselink JW. Pregnancy and adult congenital heart disease. Expert Rev Cardiovasc Ther 2007; 5(5): 859–869.

36. Tinetti ME, Bogardus Jr ST and Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med 2004; 351(27): 2870–2874.

37. Tinetti ME, Fried TR and Boyd CM. Designing health care for the most common chronic condition—multimorbidity. JAMA 2012; 307(23): 2493–2494.

38. Bateman BT and Gagne JJ. The Obstetric Comorbidity Index predicts severe maternal morbidity. BJOG 2015; 122(13): 1756.

39. Chatterjee S, Kotelchuck M and Sambamoorthi U. Prevalence of chronic illness in pregnancy, access to care, and health care costs: implications for interconception care. Womens Health Issues 2008; 18(6 Suppl): S107–S116.

40. Misra DP, Grason H and Weisman C. An intersection of women’s and perinatal health: the role of chronic conditions. Womens Health Issues 2000; 10(5): 256–267.

41. Kappel C, Rushton M, Johnson C, et al. Clinical experience of patients referred to a multidisciplinary cardio-oncology clinic: an observational cohort study. Curr Oncol 2019; 26(3): e322–e327.

42. Freund T, Kunz CU, Ose D, et al. Patterns of multimorbidity in primary care patients at high risk of future hospitalization. Pop Health Manag 2012; 15(2): 119–124.

43. Cornell JE, Pugh JA, Williams Jr JW, et al. Multimorbidity clusters: clustering binary data from multimorbidity clusters: clustering binary data from a large administrative medical database. Appl Multivar Res 2008; 12(3): 163–182.

44. Lean SC, Derricott H, Jones RL, et al. Advanced maternal age and adverse pregnancy outcomes: A systematic review and meta-analysis. PLoS One 2017; 12(10): e0186287.

45. Huda SS, Brodie LE and Sattar N. Obesity in pregnancy: prevalence and metabolic consequences. Semin Fetal Neonatal Med 2010; 15(2): 70–76.